首页> 外文期刊>Molecular medicine reports >A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles
【24h】

A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles

机译:血清microRNA信号作为晚期NSCLC患者的预后因素及其与组织microRNA表达谱的关系

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present study was to detect microRNA (miRNA) signatures in advanced non-small cell lung cancer (NSCLC), and to study the association between miRNA expression levels in serum and tissue. A cohort of patients who had previously been diagnosed with advanced NSCLC was enrolled in the present study. miRNAs associated with prognosis, which had previously been detected in early stage NSCLC samples, were measured in the serum of the patient groups using a cross-validation method. In addition, serum miRNAs associated with progression-free survival (PFS) were detected in paired fresh tissue samples, in order to analyze the correlation between serum and tissue expression levels. A risk-score analysis was used to develop a four-miRNA signature to predict PFS. miR-1, miR-30d, miR-221 and miR-486 were identified as having a significant correlation with PFS in advanced NSCLC. miR-221 and miR-486 exhibited significant positive correlations between serum and tissue expression. Furthermore, overexpression of miR-221 and reduced expression of miR-486 increased cell proliferation, migration and invasion in vitro. In conclusion, the miRNA signature identified in the present study may be considered an independent prognostic factor of PFS in advanced NSCLC. In addition, the expression levels of miR-221 and miR-486 were significantly correlated between serum and tissue. miR-221 was identified as an oncogenic risk factor, whereas miR-486 exerted protective effects against cancer cell proliferation, migration and invasion.
机译:本研究的目的是检测晚期非小细胞肺癌(NSCLC)中的microRNA(miRNA)信号,并研究血清和组织中miRNA表达水平之间的关联。本研究纳入了一组先前被诊断为晚期NSCLC的患者。使用交叉验证方法,在患者组的血清中测量了先前在早期NSCLC样本中检测到的与预后相关的miRNA。此外,在配对的新鲜组织样本中检测到了与无进展生存期(PFS)相关的血清miRNA,以分析血清与组织表达水平之间的相关性。风险评分分析用于开发四个miRNA签名来预测PFS。在晚期非小细胞肺癌中,miR-1,miR-30d,miR-221和miR-486与PFS有显着相关性。 miR-221和miR-486在血清和组织表达之间显示出显着的正相关。此外,miR-221的过表达和miR-486的减少表达增加了细胞的增殖,迁移和侵袭。总之,在本研究中确定的miRNA标记可被认为是晚期NSCLC中PFS的独立预后因素。另外,miR-221和miR-486的表达水平在血清和组织之间显着相关。 miR-221被确定为致癌危险因素,而miR-486对癌细胞的增殖,迁移和侵袭具有保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号